The IPO includes a fresh issue of Rs 95 crore along with an offer for sale of up to 1.35 crore shares. The subscription window will remain open until November 25. At the higher end of the price range, the total issue size is Rs 895 crore.
Sudeep Pharma IPO Subscription Update
On the first day of bidding, there was strong investor interest in Sudeep Pharma’s IPO with the issue being subscribed a total of 1.42 times, according to BSE data.
Retail Individual Investors (RIIs): The retail portion was subscribed 1.50 times, creating demand for more shares than the 52.82 lakh shares reserved for this category. This indicates healthy participation from small investors.
Non-Institutional Investors (NIIs): The NII category saw even stronger interest and was subscribed three times against the allotment of 22.63 lakh shares, reflecting robust interest from high net worth and other non-institutional investors.
Qualified Institutional Buyers (QIBs): QIBs subscribed to 9% of their allotted shares of Rs 30.18 lakh on Day 1. Lower initial participation from institutions is common, as they typically place larger bids closer to the final day.
IPO details of Sudeep Pharma
Sudeep Pharma’s IPO worth Rs 895 crore includes a fresh issue of Rs 95 crore and an offer for sale (OFS) of shares of 1.35 crore, amounting to Rs 800 crore.
The IPO opened for subscription on November 21, 2025 and will remain open till November 25, 2025. The allotment is expected on November 26, 2025, and the company is likely to list on the BSE and NSE on November 28, 2025. The price band for the issue has been fixed at Rs 563-Rs 593 per share.
Ahead of the public issue, the company raised Rs 268 crore from leading anchor investors by allotting 45.27 lakh shares at Rs 593 each. Participation came from major domestic mutual funds such as SBI, ICICI Prudential and HDFC, along with well-known investors including Mukul Agarwal and Prashant Jain.
Business snapshot
Sudeep Pharma is a technology-driven manufacturer specializing in excipients and specialty ingredients used in pharmaceuticals, foods and nutrition. The company offers a portfolio of more than 100 products and has developed strong capabilities in encapsulation, spray drying, granulation, trituration, liposomal processing and blending. It is also one of the world’s largest producers of food-grade iron phosphate, a key ingredient in infant and clinical nutrition.
The company has an annual production capacity of 72,246 tonnes and has several regulatory approvals, including a USFDA approved facility for mineral-based ingredients, a key advantage for global supply. The products are exported to the US, South America, Europe, the Middle East, Africa and the Asia-Pacific region.
Financially, Sudeep Pharma has shown consistent growth. Revenue rose from Rs 428.7 crore in FY23 to Rs 502 crore in FY25, while net profit rose from Rs 60.4 crore to Rs 137 crore in the same period. In the first quarter of FY26, the company posted a revenue of Rs 124.9 crore and a profit of Rs 28.4 crore.
Industry Outlook
The Indian food and nutrition ingredients industry is growing rapidly, driven by increasing health consciousness and higher disposable incomes. The total food ingredients market, estimated at USD 22 billion in 2024, is expected to reach USD 32 billion by 2029, registering a CAGR of 8.1%. The vitamin and mineral segment alone, which will be worth $2.1 billion in 2024, is expected to grow to $3 billion by 2029.
The domestic pharmaceutical sector is also on a strong growth trajectory and is expected to reach $130 billion by 2030, with the potential to scale to $450 billion by 2047. With rising demand for specialty ingredients in drug formulations and nutritional products, Sudeep Pharma is strategically positioned to benefit from multiple long-term tailwinds in the industry.
Broker View: Suitable for long-term investors
Master Capital Services has given a favorable outlook for Sudeep Pharma’s IPO, underscoring the company’s strong position in a fast-growing market and its lead in technology-driven manufacturing.
The broker points out that the rapid growth of India’s pharmaceutical, food and nutrition sectors provides a supportive environment for the company’s broad product portfolio. Thanks to its robust in-house process technologies, extensive product mix and established export footprint, Sudeep Pharma is “well positioned to capitalize on future growth opportunities.”
Given the long-term structural tailwinds in ingredients and specialty chemicals, Master Capital suggests investors can view the IPO as a promising long-term investment.
(Disclaimer: The recommendations, suggestions, views and opinions expressed by the experts are their own. These do not represent the views of The Economic Times.)
#Sudeep #Pharma #IPO #Day #Strong #GMP #subscription #trend #subscribe